Recent News

ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
April 20, 2021
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ERYTECH invited by FDA to request a pre-BLA meeting F irst step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
April 19, 2021
ERYTECH Announces Completion of First Cohort i n a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer No d ose -l imiting t oxicity reported in the first dose cohor t Encouraging clinical activity observed in first patients Trial will be escalated to the next dose